DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors

DBV Technologies, a clinical-stage biopharmaceutical company focused on developing treatments for food allergies, announced the appointment of Dr. Philina Lee to its Board of Directors, effective October 30, 2025. Dr. Lee replaces Daniel Soland and will be ratified by shareholders at the upcoming annual meeting. She will also serve as a member of the Compensation Committee, increasing the board's size to ten directors.

Dr. Lee’s extensive background in the biopharmaceutical industry adds significant expertise to DBV. She previously held senior positions at Blueprint Medicines, culminating in her role as Chief Commercial Officer, where she led the successful launch of the drug AYVAKIT®. Additionally, she has served on the Board of Directors at Fusion Pharmaceuticals, contributing to both governance and research committees.

The Chairman of the Board, Michel de Rosen, expressed enthusiasm for Dr. Lee's appointment, noting her expertise in building biopharmaceutical companies and commercializing products, which will be invaluable as DBV Technologies progresses toward the potential commercialization of its flagship product, the VIASKIN® Peanut patch. Dr. Lee acknowledged the importance of her role at DBV during a critical time, particularly with ongoing efforts to advance the VIASKIN® Peanut patch for young children suffering from peanut allergies.

DBV Technologies is dedicated to addressing significant unmet medical needs in food allergies through innovative treatments. The company is currently conducting clinical trials to utilize its unique epicutaneous immunotherapy (EPIT) approach, which aims to re-educate the immune system to desensitize patients to allergens. Headquartered in Châtillon, France, DBV Technologies continues to work towards transforming care for food-allergic patients worldwide.

DBV Technologies (Euronext: DBV, Nasdaq: DBVT) recently announced the appointment of Dr. Philina Lee to its Board of Directors, an event that carries potential implications for the company’s strategic direction and market outlook. Dr. Lee's appointment reinforces a pivotal moment for DBV, particularly as the company advances its clinical-stage offering, the VIASKIN® Peanut patch, aimed at addressing peanut allergies in children.

With her substantial background at Blueprint Medicines as Chief Commercial Officer and experience on the boards of other biopharmaceutical entities, Dr. Lee brings invaluable expertise in commercialization strategies and product launches. Her appointment signals a possible strategic shift for DBV, one that could enable the company to enhance its operational efficacy as it gears up for potential product launches.

Investors should view this development as a positive indication of leadership alignment with DBV’s ongoing mission to innovate in the field of food allergies. Dr. Lee's history of successfully bringing pharmacological products to market is particularly encouraging, as the company strives to introduce a heightened level of therapeutic care through its proprietary epicutaneous immunotherapy technology.

Moreover, the inclusion of Dr. Lee on the Compensation Committee is noteworthy, as it may lead to improved talent retention and incentive alignment throughout the organization, crucial for a clinical-stage company where human capital plays a central role in success.

In light of these developments, DBV Technologies warrants a closer examination by investors. The firm is at a crossroads, balancing clinical advances with strategic leadership changes. Current shareholders may consider holding their positions, while prospective investors might find it an opportune time to initiate or increase their investment, contingent on the outcomes of DBV's upcoming clinical trials and shareholder ratifications. The evolving narrative surrounding DBV indicates a potential for growth, underlining the importance of a long-term investment horizon in the biopharmaceutical sector.